BioSpace News Archive

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023.

Jasper Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31-February 2 and February 13-16, 2023.

PetDx® – The Liquid Biopsy Company for Pets™ announced that Alejandro Bernal, DVM, MS, MBA, has been appointed as its new President and Chief Executive Officer.

Verastem Oncology (Nasdaq: VSTM) today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).

Verastem Oncology (Nasdaq:VSTM) today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employee’s acceptance of employment with the company.

Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, the healthcare division of Yas Holding LLC, announced that the Saudi Food & Drug Authority has approved the manufacturing and distribution of AVT02, a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases.

Gandeeva Therapeutics, Inc., a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy and machine learning, announced the appointment of Brenda G. Cooperstone, MD, as an independent member of its Board of Directors.